(Q33362322)

26 July 2017

1 reference

title

Unfractionated heparin: focus on a high-alert drug (English)

1 reference

26 July 2017

1 reference

Cynthia S Niccolai

1

1 reference

26 July 2017

Rodney W Hicks

2

1 reference

26 July 2017

Lynn Oertel

3

1 reference

26 July 2017

John L Francis

4

1 reference

26 July 2017

Heparin Consensus Group

5

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

24

1 reference

26 July 2017

issue

8 Pt 2

1 reference

26 July 2017

page(s)

146S-155S

1 reference

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Medication errors in the PACU: a secondary analysis of MEDMARX findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Heparin‐induced thrombocytopenia: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Temporal aspects of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

A 14-year study of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Hemorrhagic complications of anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

Low Molecular Weight Heparins in Special Populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.12.146S.36107

10.1592/PHCO.24.12.146S.36107

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference